FindTrial
Sign In

A real-world and exploratory translational study of the efficacy and safety of PD-1/PD-L1 inhibitors in Chinese patients with advanced breast cancer

A real-world and exploratory translational study of the efficacy and safety of PD-1/PD-L1 inhibitors in Chinese patients with advanced breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037905
Enrollment
Unknown
Registered
2020-09-04
Start date
2020-09-07
Completion date
Unknown
Last updated
2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Case series:PD-1/PD-L1 inhibiter

Sponsors

Shandong cancer hospital / Shandong Cancer Research Institute
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients older than 18 years with metastatic breast cancer; 2. Patients who can be treated with PD-1 / PD-L1 inhibitors; 3. Patients with traceable medical records.

Exclusion criteria

Exclusion criteria: 1. Patients are unable to understand the nature of the study and are unwilling to sign the study consent; 2. Pregnant or lactating patients; 3. Patients who are considered unsuitable for this study by researchers.

Design outcomes

Primary

MeasureTime frame
progression free survival;adverse event;—

Secondary

MeasureTime frame
objective remission rate;Duration of remission;overall survival;Clinical benefit rate;—

Countries

China

Contacts

Public ContactHuihui Li

Shandong cancer hospital / Shandong Cancer Research Institute

15553103209@163.com+86 15553103209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026